Adolescents with perinatally acquired HIV: Emerging behavioral and health needs for long-term survivors

Current Opinion in Obstetrics and Gynecology

Volumn 23, Issue 5, 2011, Pages 321-327

  Koenig, Linda J ^a   Nesheim, Steven ^a   Abramowitz, Susan ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

adherence; adolescents; long term survivors; perinatally acquired hiv; sexual risk behaviors

Indexed keywords

ALCOHOL; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CANNABIS; CONTRACEPTIVE AGENT; ILLICIT DRUG; PROTEINASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENCE; AGE DISTRIBUTION; ALCOHOL CONSUMPTION; ARTICLE; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; COGNITION; DRUG MONITORING; DRUG USE; FAMILY PLANNING; HEALTH BEHAVIOR; HEALTH EDUCATION; HEALTH SERVICE; HEALTH STATUS; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; MENTAL HEALTH; PATIENT AUTONOMY; PATIENT COMPLIANCE; PATIENT COUNSELING; PERINATAL INFECTION; PREGNANCY; PRIMIGRAVIDA; PRIORITY JOURNAL; RACISM; REPRODUCTIVE HEALTH; SEXUAL BEHAVIOR; SEXUALITY; SMOKING; SOCIAL STATUS; SUBSTANCE ABUSE; SURVIVAL TIME; SURVIVOR; UNSAFE SEX; URBAN AREA; VIRUS LOAD; VIRUS RESISTANCE; VIRUS TRANSMISSION;

ADOLESCENT; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; HEALTH BEHAVIOR; HIV INFECTIONS; HIV-1; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; MEDICATION ADHERENCE; NEEDS ASSESSMENT; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; SEX COUNSELING; SEXUAL BEHAVIOR; SURVIVORS;

EID: 81155159834     PISSN: 1040872X     EISSN: 1473656X     Source Type: Journal    
DOI: 10.1097/GCO.0b013e32834a581b     Document Type: Article

References (61)

1. Whitmore SK, Hughes D, Taylor AW, Koenig LJ. Estimated numbers and demographic characteristics of persons living with perinatally acquired HIV disease, 34 states, United States, 2007. Poster (updated for 37 states) presented at the International AIDS Conference, Vienna. July 2010.
2. Frederick T, Thomas P, Mascola L, et al. Human immunodeficiency virusinfected adolescents: a descriptive study of older children in New York City, Los Angeles County, Massachusetts and Washington, DC. Pediatr Infect Dis J 2000; 19:551-555.
3. Judd A, Doerholt K, Tookey PA, et al. Morbidity, mortality and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: planning for teenage and adult care. Clin Infect Dis 2007; 45:918-924.
4. Foster C, Judd A, Tookey P, et al. Young people in the United Kingdom and Ireland with perinatally acquired HIV: the pediatric legacy for adult services. AIDS Patient Care STDs 2009; 23:159-167.
5. Dollfus C, Le Chenadec J, Faye A, et al. Long-term outcomes in adolescents perinatally infected with HIV-1 and followed up since birth in the French Perinatal Cohort (EPF/ANRS CO10). Clin Infect Dis 2010; 52:214-224. One of the largest sample descriptions of the therapeutic, medical and physical status of perinatally HIV-infected adolescents in the era of highly active antiretroviral therapy is presented by the French Perinatal Cohort Group.
6. Wood SM, Shahb SS, Steenhoff AP, Rutstein RM. The impact of AIDS diagnoses on long-term neurocognitive and psychiatric outcomes of surviving adolescents with perinatally acquired HIV. AIDS 2009; 23:1859-1865.
7. Patel K, Hernan MA, Williams PL, et al. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study. Clin Infect Dis 2008; 46:507-515. (Pubitemid 351263487)
8. Dimock D, Thomas V, Cushing A, et al. Longitudinal assessment of metabolic abnormalities in adolescents and young adults with HIV infection acquired perinatally or in early childhood. Metabolism Clinical and Experimental 2011; 60:874-880. Long-term metabolic abnormalities (impaired glucose tolerance, insulin resistance, elevated triglycerides and low-density lipoprotein cholesterol, and low high-density lipoprotein cholesterol) are described in a group of perinatally HIV-infected adolescents and young adults.
9. Miller TL, Orav J, Lipshultz SE, et al. Risk factors for cardiovascular disease in children infected with human immunodeficiency virus-1. J Pediatr 2008; 153:491-497.
10. Arpadi SM, Bethel J, Horlick M, et al. Longitudinal changes in regional fat content in HIV-infected children and adolescents. AIDS 2009; 23:1501-1509.
11. Aldrovandi GM, Lindsey JC, Jacobson DL, et al. Morphologic and mesolic abnormalities in vertically HIV-infected children and youth. AIDS 2009; 23:661-672.
12. McComsey GA, O'Riordan MA, Hazen SL, et al. Increased carotid intima media thickness and cardiac biomarkers in HIV infected children. AIDS 2007; 21:921-927. (Pubitemid 46684323)
13. Ross AC, Storer N, O'Riordan MA, et al. Longitudinal changes in carotid intima-media thickness and cardiovascular risk factors in Human Immunodeficiency Virus-infected children and young adults compared with healthy controls. Pediatr Infect Dis J 2010; 29:634-638.
14. Hazra R, Siberry GK, Mofenson LM. Growing up with HIV: children, adolescents and young adults with perinatally acquired HIV infection. Annu Rev Med 2010; 61:169-185. Important review of treatment issues, including formulations, drug resistance and adherence, and complications for children and adolescents with perinatally acquired HIV.
15. Foster C, Fidler S. Optimizing antiretroviral therapy in adolescents with perinatally acquired HIV-1 infection. Expert Rev Anti Infect Ther 2010; 8:1403-1416.
16. Simoni JM, Montgomery A, Martin E, et al. Adherence to antiretroviral therapy for pediatric HIV infection: a qualitative systematic review with recommendations for research and clinical management. Pediatrics 2007; 119:e1371-e1383. (Pubitemid 46871324)
17. Khan M, Song X, Williams K, et al. Evaluating adherence to medication in children and adolescents with HIV. Arch Gen Psychiatry 2008; 94:970-973.
18. Williams PL, Storm D, Montepiedra G, et al. Predictors of adherence to antiretroviral medications in children and adolescents with HIV infection. Pediatrics 2006; 118:e1745-e1757. (Pubitemid 46397550)
19. Merzel C, VanDevanter N, Irvine M. Adherence to antiretroviral therapy among older children and adolescents with HIV: a qualitative study of psychosocial contexts. AIDS Patient Care STDs 2008; 22:977-987.
20. Malee K, Williams PL, Montepiedra G, et al. The role of cognitive functioning in medication adherence of children and adolescents with HIV infection. J Pediatr Psychol 2009; 34:164-175.
21. Rudy BJ, Murphy DA, Harris R, et al. Prevalence and interactions of patientrelated risks for nonadherence to antiretroviral therapy among perinatally infected youth in the United States. AIDS Patient Care STDs 2010; 24:97-104.
22. Martin S, Elliott-DeSorbo DK, Wolters PL, et al. Patient, caregiver and regimen characteristics associated with adherence to highly active antiretroviral therapy among HIV-infected children and adolescents. Pediatr Infect Dis J 2007; 26:61-67. (Pubitemid 46045754)
23. Abramowitz S, Koenig LJ, Chandwani S, et al. Characterizing social support: global and specific support experiences of HIV infected youth. AIDS Patient Care STDs 2009; 23:323-330.
24. Koenig LJ, Bachanas PJ. Adherence to medications for HIV: teens say 'too many, too big, too often'. In: Lyon M, D'Dangelo L, editors. Teenagers, HIV and AIDS: insights from youths living with the virus. Westport, CT: Praeger; 2006. pp. 45-65..
25. Veinot TC, Flicker SE, Skinner HA, et al. 'Supposed to make you better but it doesn't really': HIV-positive youths' perceptions of HIV treatment. J Adolesc Health 2006; 38:261-267. (Pubitemid 43247517)
26. Brogly SB, Watts DH, Ylitalo N, et al. Reproductive health of adolescent girls perinatally infected with HIV. Am J Public Health 2007; 97:1047-1052. (Pubitemid 351181927)
27. Ezeanolue E, Wodi A, Patel R, et al. Sexual behaviors and procreational intentions of adolescents and young adults with perinatally acquired human immunodeficiency virus infection: experience of an urban tertiary center. J Adolesc Health 2006; 38:719-725.
28. Koenig LJ, Pals SL, Chandwani S, et al. Sexual transmission risk behaviors of adolescents with HIV acquired perinatally or through risky behaviors. J Acquir Immune Defic Syndr 2010; 55:380-390. Descriptions of sexual history (age of onset, sexual abuse, types of sex engaged in) and transmission risk behaviors (partner disclosure, unprotected sex) of adolescents with perinatally acquired HIV are included in this first study to assess partner HIV exposure.
29. Wiener LS, Battles HB, Wood RW. A longitudinal study of adolescents with perinatally or transfusion acquired HIV infection: Sexual knowledge, risk reduction self-efficacy and sexual behavior. AIDS Behav 2007; 11:471-478. (Pubitemid 46570812)
30. Youth Risk Behavior Surveillance System (YRBSS). Youth online (2009 data). http://www.cdc.gov/healthyyouth/yrbs/index.htm. [Accessed 15 June 2011].
31. Abrams E, Wiener J, Carter R, et al. Maternal health factors and early pediatric antiretroviral therapy influence the rate of perinatal HIV-1 disease progression in children. AIDS 2003; 17:867-877. (Pubitemid 36547659)
32. Fernet M, Wong K, Richard M, et al. Romantic relationships and sexual activities of the first generation of youth living with HIV since birth. AIDS Care 2011; 23:393-400.
33. American Academy of Pediatrics Committee on Pediatric AIDS. Disclosure of illness status to children and adolescents with HIV infection. Pediatrics 1999; 103:164-166.
34. Santamaria EK, Dolezal C, Marhefka SL, et al. Psychosocial implications of HIV serostatus disclosure to youth with perinatally acquired HIV. AIDS Patient Care STDs 2011; 25:257-264. In a cohort of HIV-positive youth aged 9-16, disclosed youth (who had been told their serostatus) did not show an increase of psychological problems and were more likely to have intentions to self-disclose to sexual partners. Yet, almost onethird of participants were entering puberty without important information regarding their illness.
35. Michaud P, Suris J, Thomas LR, et al. To say or not to say: a qualitative study on the disclosure of their condition by human immunodeficiency virus-positive adolescents. J Adolesc Health 2009; 44:356-362.
36. Arnold EM, Rice E, Flannery D, Rotheram-Borus MJ. HIV disclosure among adults living with HIV. AIDS Care 2008; 20:80-92. (Pubitemid 351264540)
37. Childs J, Maxwell M. Psychosocial snapshots: perinatally infected HIV+ adolescents' sexual behaviors and pregnancies. Soc Work Healthcare 2009; 48:777-797.
38. Leonard C, Markham CM, Bui T, et al. Lowering the risk of secondary HIV transmission: insights from HIV-positive youth and healthcare providers. Perspect Sex Reprod Health 2010; 42:110-116.
39. Elkington KS, Bauermeister JA, Brackis-Cott E, et al. Substance use and sexual risk behaviors in perinatally human immunodeficiency virus-exposed youth: roles of caregivers, peers and HIV status. J Adolesc Health 2009; 45:133-141.
40. Conner LC, Wiener J, Lewis JV, et al. Prevalence and predictors of drug use among adolescents with HIV infection acquired perinatally or later in life. AIDS Behav (in press).
41. Williams PL, Leister E, Chernoff M, et al. Substance use and its association with psychiatric symptoms in perinatally HIV-infected and HIV-affected adolescents. AIDS Behav 2010; 14:1072-1082. Data from the IMPAACT P1055 study are used to compare the association between substance use and psychiatric illness symptoms between adolescents with perinatally acquired HIV and those in families affected by HIV. Odds of substance use were higher among those with psychiatric symptoms regardless of HIV status.
42. Zorilla C, Febo I, Ortiz I, et al. Pregnancy in perinatally HIV-infected adolescents and young adults - Puerto Rico. MMWR Morbid Mortality Wkly Rep 2003; 52:149-151.
43. Levine A, Aaron E, Foster J. Pregnancy in perinatally HIV-infected adolescents. J Adolesc Health 2006; 38:765-768. (Pubitemid 43765848)
44. Crane S, Sullivan M, Feingold M, Kaufman GE. Successful pregnancy in an adolescent with perinatally acquired human immunodeficiency virus. Am J Obstet Gynecol 1998; 92:711. (Pubitemid 28440807)
45. Williams SF, Keane-Tarchichi MH, Bettica L, et al. Pregnancy outcomes in young women with perinatally acquired human immunodeficiency virus-1. Am J Obstet Gynecol 2009; 200:e1-e5. A hospital-based case series from the United States describes the pregnancies of 10 perinatally HIV-infected young mothers.
46. Centers for Disease Control and Prevention. Vital signs: teen pregnancy - United States, 1991-2009. MMWR Morbid Mortality Wkly Rep 2011; 60:414-420.
47. Nachman S, Chernoff M, Gona P, et al. Incidence of noninfectious conditions in perinatally HIV-infected children and adolescents in the HAART era. Arch Pediatr Adolesc Med 2009; 163:164-171. A large United States cohort of HIV-infected children and adolescents followed in Pediatric AIDS Clinical Trials Group 219C during the era of highly active antiretroviral therapy documents incidence rates of noninfectious diagnoses, among which pregnancy-related conditions were most common.
48. Koenig LJ, Espinoza L, Hodge K, Ruffo N. Young, seropositive, and pregnant: epidemiologic and psychosocial perspectives on pregnant adolescents with human immunodeficiency virus infection. Am J Obstet Gynecol 2007; 197:S123-S131. (Pubitemid 47354186)
49. Thorne C, Townsend CL, Peckham CS, et al. Pregnancies in young women with vertically acquired HIV infection in Europe. AIDS 2007; 21:2552-2555.
50. World Health Organization. Medical eligibility criteria for contraceptive use - 4th ed. Geneva, Switzerland: World Health Organization; 2009. (copyright 2010).
51. Panel on Antiretroviral Therapy and Medical Management of HIV-infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection [16 August 2010]. pp. 1-219. Available at http://adsinfo.nih.gov/ ContentFiles/PediatricGuidelines.pdf. [Accessed 16 June 2011]. p. 78.
52. Centers for Disease Control and Prevention. U.S. medical eligibility criteria for contraceptive use, 2010. MMWR Morbid Mortal Wkly Rep 2010; 59:1-6.
53. Brady SS, Dolcini MM, Harper GW, Pollack LM. Supportive friendships moderate the association between stressful life events and sexual risk taking among African American adolescents. Health Psychol 2009; 28:238-248.
54. Mellins CA, Brackis-Cott E, Leu CS, et al. Rates and types of psychiatric disorders in perinatally human immunodeficiency virus-infected youth and seroreverters. J Child Psychol Psychiatry 2009; 50:1131-1138. Prevalence of psychiatric and substance use disorders in HIV-positive and uninfected HIV-exposed children and adolescents are compared. Although a high percentage of HIV-positive and HIV-uninfected youth met criteria for psychiatric disorders, rates were significantly higher among HIV-positive youth.
55. Souza E, Santos N, Valentini S, et al. Long-term follow-up outcomes of perinatally HIV-infected adolescents: infection control but school failure. J Trop Pediatr 2010; 56:421-426.
56. Gadow KD, Chernoff M, Williams PL, et al. Co-occurring psychiatric symptoms in children perinatally infected with HIV and peer comparison sample. J Dev Behav Pediatr 2010; 31:116-128. Data from the International Maternal Adolescent AIDS Clinical Trials (IMPAACT) 1055 study are used to compare the prevalence of psychopathology and behavioral treatments in perinatally infected children and adolescents to that of a control group. Rates and severity of psychopathology in HIV-infected youth and their peers were comparable, although HIV-infected youth had greater lifetime rates of special education, pharmacological and behavioral interventions.
57. Orban L, Stein RR: Koenig LJ, et al. Coping styles of youth with HIV: disease specific stressors and responses. AIDS Care 2010; 22:420-430.
58. Marhefka S, Lyon M, Koenig LJ, et al. Emotional and behavioral problems and mental health service utilization of youth living with HIV acquired perinatally or later in life. AIDS Care 2009; 21:1447-1454.
59. Chernoff M, Nachman S, Williams P, et al. Mental health treatment patterns in perinatally HIV-infected youth and controls. Pediatrics 2009; 124:627-636. Using data from the International Maternal Adolescent AIDS Clinical Trials (IMPAACT) 1055 study, receipt of psychotropic medication and behavioral treatments in perinatally infected youth and a control group were compared. Prevalence of psychiatric symptoms and impairment were similar in infected youth and controls, but perinatally infected youth and youth whose caregivers reported on their child's symptoms were more likely to have received behavior or medication interventions for psychological problems.
60. Mellins CA, Smith R, O'Driscoll P, et al. High rates of behavioral problems in perinatally HIV-infected children are not linked to HIV disease. Pediatrics 2003; 111:384-393. (Pubitemid 36177160)
61. Brackis-Cott E, Kang E, Dolezal C, et al. The impact of perinatal HIV infection on older school-aged children's and adolescents' receptive language and word recognition skills. AIDS Patient Care STDs 2009; 23:415-421.